Tag: M.W=200-250

Loriga, Mario; Fiore, Maria; Sanna, Paolo; Paglietti, Giuseppe published the artcile< Quinoxaline chemistry. Part 4. 2-(R)-Anilinoquinoxalines as nonclassical antifolate agents. Synthesis, structure elucidation and evaluation of in vitro anticancer activity>, COA of Formula: C8H4ClN3O2, the main research area is anilinoquinoxaline derivative preparation neoplasm inhibitor; quinoxaline anilino derivative preparation antitumor.

Thirty-five quinoxalines bearing a substituted aniline group on position 2 and various substituents on positions 3,6,7 and 8 were prepared in order to evaluate in vitro anticancer activity. Structural elucidation of some isomeric quinoxalinones formed by ring closure of 4-substituted-1,2-diaminobenzenes with dicarbonyl compounds was achieved by comparison with one isomer coming from an unambiguous independent route. Preliminary in vitro screening at NCI showed that many compounds exhibited a moderate to strong growth inhibition activity on various cells lines between 10-5 and 10-4 molar concentrations

Farmaco published new progress about Antitumor agents. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, COA of Formula: C8H4ClN3O2.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Arienzo, Rosa; Cramp, Sue; Dyke, Hazel J.; Lockey, Peter M.; Norman, Dennis; Roach, Alan G.; Smith, Phil; Wong, Melanie; Wren, Stephen P. published the artcile< Quinazoline and benzimidazole MCH-1R antagonists>, Category: quinoxaline, the main research area is quinazoline derivative preparation MCH 1R antagonist; benzimidazole derivative preparation MCH 1R antagonist.

Two novel series of MCH-1R antagonists were obtained by modification of previous reported 2-aminoquinoline derivatives Representative quinazoline compound I and benzimidazole derivative II were shown to be potent and selective, with promising in vitro eADME profiles.

Bioorganic & Medicinal Chemistry Letters published new progress about Amidation. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Category: quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Lumma, William C. Jr.; Hartman, Richard D.; Saari, Walfred S.; Engelhardt, Edward L.; Lotti, Victor J.; Stone, Clement A. published the artcile< Piperazinylquinoxalines with central serotoninmimetic activity>, Computed Properties of 6272-25-9, the main research area is serotoninmimetic piperazinylquinoxaline; serotoninin reuptake blocking quinoxaline; piperazinylquinoxaline; quinoxaline piperazinyl.

The piperazinylquinoxalines I (R = H, Ac, Me; R1 = H, OH (and the related ketone), CO2H; R2, R3 = H, Cl, NH2, CF3, SPh, OMe, F, etc.; m, n = 0, 1) were prepared by various methods. I were tested for selectivity in regards to serotonin reuptake blocking and serotoninmimetic activity. In general, introduction of a 6-substituent into I enhanced serotonin reuptake blocking activity and diminished serotoninmimetic activity. Unsubstituted I and I (R1 = OH) had primary serotoninmimetic activity.

Journal of Medicinal Chemistry published new progress about 6272-25-9. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Computed Properties of 6272-25-9.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Hazeldine, Stuart T.; Polin, Lisa; Kushner, Juiwanna; Paluch, Jennifer; White, Kathryn; Edelstein, Matthew; Palomino, Eduardo; Corbett, Thomas H.; Horwitz, Jerome P. published the artcile< Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)>, Reference of 6272-25-9, the main research area is chloroquinoxalinyloxyphenoxypropionic acid structure antitumor; quinoxalinyloxyphenoxypropionic acid antitumor preparation.

2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469) I is among the most highly and broadly active antitumor agents to have been evaluated and scheduled to enter clin. trials in 2001. The mechanism or mechanisms of action of I remain to be elaborated. Accordingly, an effort was initiated to establish a pharmacophore hypothesis to delineate the requirements of the active site, via a comprehensive program of synthesis of analogs of I and evaluation of the effects of structural modification(s) on solid tumor activity. The strategy formulated chose to dissect the two-dimensional parent structure into three regions: I, ring A of quinoxaline; II, the hydroquinone connector linkage; and III, the lactic acid moiety-to determine the resultant in vitro and in vivo effects of chem. alterations in each region. Neither the A-ring unsubstituted nor the B-ring 3-chloro-regioisomer of I showed antitumor activity. The modulating antitumor effect(s) of substituents of differing electronegativities, located at the several sites comprising the A-ring of region I, were next ascertained. Thus, a halogen substituent, located at the 7-position of a 2-{4-[(2-quinoxalinyl)oxy]phenoxy}propionic acid, generated the most highly and broadly active antitumor agents. A Me, methoxy, or an azido substituent at this site generated a much less active structure, whereas 5-, 6-, 8-chloro-, 6-, 7-nitro, and 7-amino derivatives all proved to be essentially inactive. When the connector linkage (region II) of I was changed from that of a hydroquinone to either a resorcinol or a catechol derivative, all antitumor activity was lost. Of the carboxylic acid derivatives of I (region III), i.e., CONH2, CONHMe, CONMe2, CONHOH, CONHNH2, CN, or CN4H (tetrazole), only the monomethyl- and N,N-dimethylamides proved to be active.

Journal of Medicinal Chemistry published new progress about Antitumor agents. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Reference of 6272-25-9.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Lumma, William C. Jr.; Hartman, Richard D.; Saari, Walfred S.; Engelhardt, Edward L.; Lotti, Victor J.; Stone, Clement A. published the artcile< Piperazinylquinoxalines with central serotoninmimetic activity>, Category: quinoxaline, the main research area is serotoninmimetic piperazinylquinoxaline; serotoninin reuptake blocking quinoxaline; piperazinylquinoxaline; quinoxaline piperazinyl.

The piperazinylquinoxalines I (R = H, Ac, Me; R1 = H, OH (and the related ketone), CO2H; R2, R3 = H, Cl, NH2, CF3, SPh, OMe, F, etc.; m, n = 0, 1) were prepared by various methods. I were tested for selectivity in regards to serotonin reuptake blocking and serotoninmimetic activity. In general, introduction of a 6-substituent into I enhanced serotonin reuptake blocking activity and diminished serotoninmimetic activity. Unsubstituted I and I (R1 = OH) had primary serotoninmimetic activity.

Journal of Medicinal Chemistry published new progress about 6272-25-9. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Category: quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Hazeldine, Stuart T.; Polin, Lisa; Kushner, Juiwanna; Paluch, Jennifer; White, Kathryn; Edelstein, Matthew; Palomino, Eduardo; Corbett, Thomas H.; Horwitz, Jerome P. published the artcile< Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)>, Category: quinoxaline, the main research area is chloroquinoxalinyloxyphenoxypropionic acid structure antitumor; quinoxalinyloxyphenoxypropionic acid antitumor preparation.

2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469) I is among the most highly and broadly active antitumor agents to have been evaluated and scheduled to enter clin. trials in 2001. The mechanism or mechanisms of action of I remain to be elaborated. Accordingly, an effort was initiated to establish a pharmacophore hypothesis to delineate the requirements of the active site, via a comprehensive program of synthesis of analogs of I and evaluation of the effects of structural modification(s) on solid tumor activity. The strategy formulated chose to dissect the two-dimensional parent structure into three regions: I, ring A of quinoxaline; II, the hydroquinone connector linkage; and III, the lactic acid moiety-to determine the resultant in vitro and in vivo effects of chem. alterations in each region. Neither the A-ring unsubstituted nor the B-ring 3-chloro-regioisomer of I showed antitumor activity. The modulating antitumor effect(s) of substituents of differing electronegativities, located at the several sites comprising the A-ring of region I, were next ascertained. Thus, a halogen substituent, located at the 7-position of a 2-{4-[(2-quinoxalinyl)oxy]phenoxy}propionic acid, generated the most highly and broadly active antitumor agents. A Me, methoxy, or an azido substituent at this site generated a much less active structure, whereas 5-, 6-, 8-chloro-, 6-, 7-nitro, and 7-amino derivatives all proved to be essentially inactive. When the connector linkage (region II) of I was changed from that of a hydroquinone to either a resorcinol or a catechol derivative, all antitumor activity was lost. Of the carboxylic acid derivatives of I (region III), i.e., CONH2, CONHMe, CONMe2, CONHOH, CONHNH2, CN, or CN4H (tetrazole), only the monomethyl- and N,N-dimethylamides proved to be active.

Journal of Medicinal Chemistry published new progress about Antitumor agents. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Category: quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Shahin, Mai I.; Abou El Ella, Dalal A.; Ismail, Nasser S. M.; Abouzid, Khaled A. M. published the artcile< Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold>, Synthetic Route of 6272-25-9, the main research area is arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline preparation VEGFR2 inhibitor; structure arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline inhibition VEGFR2 kinase; mol docking arylaminoquinoxalinone arylaminoquinoxaline ATP binding site VEGFR2; calculated lipophilicity solubility absorption CYP 2D6 inhibition arylaminoquinoxalinone arylaminoquinoxaline; Docking study; Kinase; Quinoxaline; Type-II; VEGFR-2.

Arylaminoquinoxalinones I [R = HO; R1 = 4-MeOC6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, 2-HO2CC6H4CONH, MeCONH; R3 = Ph, 3-ClC6H4, 3-MeC6H4, cyclohexyl; R4 = H, Me; X = O, S], arylaminoquinoxalines I [R = H; R1 = 4-R5C6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, MeCONH; R3 = Ph, 3-MeC6H4, cyclohexyl; R4 = H, Me; R5 = MeO, Cl; X = O, S] and ureidoarylaminoquinoxalines I [R = H; R1 = 4-(3-R6C6H4NHCONH)C6H4NH; R2 = O2N; R6 = H, Cl] were prepared as ATP-competitive VEGFR-2 inhibitors for potential use as antitumor agents. I (R = HO; R1 = 4-MeOC6H4; R2 = PhNHCONH) was the most effective VEGFR-2 inhibitor of the compounds prepared at a concentration of 10 μM. Mol. docking calculations were performed to rationalize the selectivities of quinoxalines for VEGFR-2; calculated physicochem. properties, absorption, and probabilities of CYP 2D6 inhibition were determined for the compounds

Bioorganic Chemistrypublished new progress about Biological permeation. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Synthetic Route of 6272-25-9.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider